Please login to the form below
ulcerative colitis
This page shows the latest ulcerative colitis news and features for those working in and with pharma, biotech and healthcare.
Gilead and Galapagos JAK contender scores in RA trial
The results are further good news for the partners and their inflammatory conditions contender, which is also being studied in ulcerative colitis, Crohn’s disease and ankylosing spondylitis.
Latest news
-
Gilead, Galapagos JAK inhibitor clears phase II test
The drug is also in development for rheumatoid arthritis (RA), ulcerative colitis and Crohn’s disease with phase III trials already underway in those indications and results due in the coming ... Like filgotinib, upadacitinib is also being tested in a
-
Immunology keeps Shire figures solid as Takeda takeover nears
There were gains for newer products Entyvio (vedolizumab) or ulcerative colitis, up a third to around $550m, and myeloma therapy Ninlaro (ixazomib) which climbed 43% to $125m, but Takeda is predicting
-
Communiqué: big wins for obesity and sugar tax campaigners
This entry described a live ‘broadcast’meeting that provided education around excess steroid use, a standard treatment for ulcerative colitis. ... Meanwhile, Aurora Healthcare Communications’ Travel with IBD campaign for Japanese pharma group
-
Trial data suggest Abivax’ drug may clear latent HIV
Those anti-inflammatory properties have encouraged Abivax to carry out a phase 2a trial of the drug in ulcerative colitis, with results expected in September.
-
AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib
Meanwhile, following the same path as Xeljanz, upadacitinib is also being tested in a string of other indications, including psoriatic arthritis, Crohn’s disease, ulcerative colitis and atopic dermatitis.
More from news
Approximately 19 fully matching, plus 109 partially matching documents found.
Latest Intelligence
-
Taking a lean and careful approach
ulcerative colitis, type 1 diabetes and inflammatory bowel disease.
-
Making digital health personal
Personalisation: A case study. This case study is of a digital health support programme that improved persistence of people with ulcerative colitis.
-
Deal Watch January 2017
Assembly Biosciences. Allergan. Exclusive global licence . 2 pc candidates for ulcerative colitis (ABI-M201) and Crohn's disease plus 2 compounds for IBS.
-
Forging a path in specialty care
Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA
-
Biosimilars - the same, but different?
The first months of 2015 also saw it approve Remsima and Inflectra for use on the NHS to treat moderately to severely active ulcerative colitis after the failure of conventional therapy.
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Lorin Johnson joins Atlantic Healthcare board
Atlantic's lead asset, alicaforsen for the treatment of the inflammatory bowel diseases ulcerative colitis and pouchitis.
-
Ex J&J VP joins board of Immune
Its lead product candidate is bertilimumab, which is in clinical development for ulcerative colitis and Crohn's Disease as well as the rare skin condition bullous pemphigoid.
-
AstraZeneca veteran Deborah Hartman joins Avaxia
AstraZeneca veteran Deborah Hartman joins Avaxia. Will lead the development of AVX-470 in ulcerative colitis. ... with active ulcerative colitis.
-
EMA’s Pharmacovigilance Risk Assessment Committee gains new members
Their respective alternates are Kirsten Myhr, from the Norwegian Board of Health, and Marco Greco, from the European Federation Crohn's and Ulcerative Colitis Associations.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
News: Research Partnership launches new patient report - Living with Ulcerative Colitis
News: Research Partnership launches new patient report - Living with Ulcerative Colitis. ... Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5
-
Research Partnership has published a new Living with Ulcerative Colitis (UC) US market report for 2017
Research Partnership has published a new Living with Ulcerative Colitis (UC) US market report for 2017. ... Living with Ulcerative Colitis (UC) is a study conducted amongst 110 adult UC patients in the US.
-
Research Partnership launches new patient Living with Ulcerative Colitis (UC) US report
Research Partnership launches new patient Living with Ulcerative Colitis (UC) US report. ... Living with Ulcerative Colitis (UC) is a study conducted amongst 100 adult UC patients in the US.
-
Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016
Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016. ... Ulcerative Colitis (UC) is a progressive and debilitating disease which affects between 2.5 to 3 million people in Europe.
-
Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016
Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016. ... Ulcerative Colitis (UC) is a progressive and debilitating disease which affects between 2.5 to 3 million people in Europe.
More from PMHub
Approximately 5 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Associate Scientific Director
-
Salary TBC
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Account Director or Senior Account Director
-
Salary TBC
- Sudler London - Senior Medical Writer
-
Competitive
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Sudler London - Account Director
-
Competitive
-
Systematic Review Lead- London
-
Negotiable
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
-
Account Manager
-
Negotiable
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Senior Medical Writer
-
Salary is DOE
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
Subscribe to our email news alerts
- Moving annual total (MAT)
- Key success factor (KSF)
- AZ prepares to file COPD triple, taking on rival GSK
- Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
- Gilead targets hep B in half a billion dollar deal with Precision BioSciences
- Teva wins FDA OK for crucial migraine drug
- IPA’s new training course, Silver Buck launched and ARK moves office
- NHS wins legal fight with pharma over off-label Avastin
- Gilead and ViiV among winners at PM Society Digital Awards
- The critical role of science in healthcare communications
- UK pharma to work with innovation network on NHS uptake
- Bayer roll-out of haemophilia drug Jivi gathers pace
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
